MAS related GPR family member X2Genealiases: MGRG3 · MRGX2
Q-omics provides the consensus-scored MRGPRX2 profile across patient tissues and cancer cell-line models. MRGPRX2 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MRGPRX2 is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, MRGPRX2 RNA expression shows 7,514 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, COAD, and TGCT as cancer lineages where MRGPRX2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MRGPRX2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MRGPRX2 survival associations across molecular data types. MRGPRX2 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MRGPRX2 RNA expression–survival associations across cancer types. High MRGPRX2 expression shows unfavorable associations in LIHC and TGCT, but favorable associations in KIRC, MESO, HNSC and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .005). Together, the overview and detailed table identify KIRC as the clearest survival context for MRGPRX2 RNA expression.
This table summarizes MRGPRX2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for MRGPRX2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MRGPRX2 shows lower tumor expression in COAD, BRCA, BLCA, READ, UCEC and LUAD. The COAD box plot shows higher MRGPRX2 RNA expression in normal versus tumor tissue (log2 FC = −0.137, t-test p < 0.001).
This table shows molecular features associated with MRGPRX2 in patient tissues and cancer cell lines. In patient samples, MRGPRX2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, MRGPRX2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and LARGE_INTESTINE.
